Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Hutti, Jessica E ^a   Porter, Melissa A ^a   Cheely, Adam W ^a   Cantley, Lewis C ^b,c   Wang, Xiaodong ^a   Kireev, Dmitri ^a   Baldwin, Albert S ^a   Janzen, William P ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE EPSILON; I KAPPA B KINASE INHIBITOR; TANK BINDING KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ENZYME ASSAYS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; I-KAPPA B KINASE; KINETICS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY;

EID: 84864478203     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041494     Document Type: Article

References (36)

1. Ben-Neriah Y, Karin M, ((2011)) Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12:: 715--723.
2. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, et al. ((2011)) Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev 25:: 2125--2136.
3. Oeckinghaus A, Hayden MS, Ghosh S, ((2011)) Crosstalk in NF-kappaB signaling pathways. Nat Immunol 12:: 695--708.
4. Wild P, Farhan H, McEwan DG, Wagner S, Rogov VV, et al. ((2011)) Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 333:: 228--233.
5. Basseres DS, Baldwin AS, ((2006)) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:: 6817--6830.
6. Clement JF, Meloche S, Servant MJ, ((2008)) The IKK-related kinases: from innate immunity to oncogenesis. Cell Res 18:: 889--899.
7. Hacker H, Karin M, ((2006)) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006:: re13.
8. Hayden MS, Ghosh S, ((2004)) Signaling to NF-kappaB. Genes Dev 18:: 2195--2224.
9. Shen RR, Hahn WC, ((2011)) Emerging roles for the non-canonical IKKs in cancer. Oncogene 30:: 631--641.
10. Clement JF, Bibeau-Poirier A, Gravel SP, Grandvaux N, Bonneil E, et al. ((2008)) Phosphorylation of IRF-3 on Ser 339 generates a hyperactive form of IRF-3 through regulation of dimerization and CBP association. J Virol 82:: 3984--3996.
11. Mori M, Yoneyama M, Ito T, Takahashi K, Inagaki F, et al. ((2004)) Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. J Biol Chem 279:: 9698--9702.
12. Panne D, McWhirter SM, Maniatis T, Harrison SC, ((2007)) Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch. J Biol Chem 282:: 22816--22822.
13. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, et al. ((2007)) Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 315:: 1274--1278.
14. tenOever BR, Sharma S, Zou W, Sun Q, Grandvaux N, et al. ((2004)) Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity. J Virol 78:: 10636--10649.
15. Peters RT, Liao SM, Maniatis T, ((2000)) IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol Cell 5:: 513--522.
16. Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, et al. ((2000)) NAK is an IkappaB kinase-activating kinase. Nature 404:: 778--782.
17. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, et al. ((2007)) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:: 1065--1079.
18. Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, et al. ((2006)) RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127:: 157--170.
19. Guo JP, Shu SK, He L, Lee YC, Kruk PA, et al. ((2009)) Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol 175:: 324--333.
20. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, et al. ((2009)) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:: 108--112.
21. Clark K, Plater L, Peggie M, Cohen P, ((2009)) Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 284:: 14136--14146.
22. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, et al. ((2005)) Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 280:: 19867--19874.
23. Wang T, Block MA, Cowen S, Davies AM, Devereaux E, et al. ((2012)) Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett 22:: 2063--2069.
24. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, et al. ((2009)) Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 34:: 461--472.
25. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, et al. ((2007)) IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol 27:: 7451--7461.
26. Marinis JM, Hutti JE, Homer CR, Cobb BA, Cantley LC, et al. ((2012)) IkappaB Kinase alpha Phosphorylation of TRAF4 Downregulates Innate Immune Signaling. Mol Cell Biol 32:: 2479--2489.
27. Hutti JE, Jarrell ET, Chang JD, Abbott DW, Storz P, et al. ((2004)) A rapid method for determining protein kinase phosphorylation specificity. Nat Methods 1:: 27--29.
28. Turk BE, Hutti JE, Cantley LC, ((2006)) Determining protein kinase substrate specificity by parallel solution-phase assay of large numbers of peptide substrates. Nat Protoc 1:: 375--379.
29. Kotturi P, Boudreau M (2003) Mobility shift screening assays for protein kinase targets. American Laboratory 35: 32-+.
30. Sundberg SA, Chow A, Nikiforov T, Wada HG, ((2000)) Microchip-based systems for target validation and HTS. Drug Discov Today 5:: 92--103.
31. Card A, Caldwell C, Min H, Lokchander B, Hualin X, et al. ((2009)) High-throughput biochemical kinase selectivity assays: panel development and screening applications. J Biomol Screen 14:: 31--42.
32. Bernasconi P, Chen M, Galasinski S, Popa-Burke I, Bobasheva A, et al. ((2007)) A chemogenomic analysis of the human proteome: application to enzyme families. J Biomol Screen 12:: 972--982.
33. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, ((2001)) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:: 3--26.
34. Casella G, Berger RL (2002) Statistical inference. Australia; Pacific Grove, CA: Thomson Learning. xxviii, 660 p.
35. Pipeline Pilot, ver. 8.5. Accelrys Software Inc.
36. Walters WP, Ajay, Murcko MA, ((1999)) Recognizing molecules with drug-like properties. Curr Opin Chem Biol 3:: 384--387.